×

AstraZeneca: Enhertu Triples Progression-free Survival In Phase III DESTINY-Breast03 Trial

Published Sep 20 2021 at 6:29 AM GMT
Key
Points
  • L, AZN) said detailed positive results from the head-to-head DESTINY-Breast03 Phase III trial showed that Enhertu showed superior progression-free survival compared to trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.
  • At a prespecified interim analysis of DESTINY-Breast03, Enhertu showed.




Trending

Stats

  • Published Sep 20, 2021 6:29 AM GMT